Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sunil Patel

Internal Medicine Western Springs, IL Medical Doctor

NPI 1801987565 CMS profile 308474

5108 Central Ave, Western Springs, IL 60558

Open in the dashboard

General payments

$6,735

415 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,689 paid to institutions, not to them · program year 2019

Through program year 2025, Sunil Patel of Western Springs, IL is reported in the CMS Open Payments database as having received $6,735 across 415 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,689 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $232 9
2024 General $272 17
2023 General $1,699 92
2022 General $1,217 68
2021 General $395 24
2020 General $741 44
2019 General $2,180 161

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sunil Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sunil Patel were reported at $232. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sunil Patel Internal Medicine median Middle half National median
2019 $2,180 $159 $48–$570 $163
2020 $741 $119 $33–$402 $114
2021 $395 $135 $37–$521 $132
2022 $1,217 $141 $42–$496 $149
2023 $1,699 $149 $45–$519 $160
2024 $272 $154 $47–$537 $164
2025 $232 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $1,208 73 payments
  2. GlaxoSmithKline, LLC. $826 56 payments
  3. Novo Nordisk Inc $549 36 payments
  4. AstraZeneca Pharmaceuticals LP $470 26 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $438 25 payments
  6. Pfizer Inc. $427 28 payments
  7. AbbVie, Inc. $421 17 payments
  8. Sanofi-Aventis U.S. LLC $284 21 payments
  9. Merck Sharp & Dohme Corporation $274 20 payments
  10. Novartis Pharmaceuticals Corporation $273 19 payments
  11. Other $1,566 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,714 412 payments
  2. Education $21 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $655 44 payments
  2. MOUNJARO $614 32 payments
  3. JARDIANCE Diabetes $441 29 payments
  4. TRULICITY $300 19 payments
  5. FARXIGA $272 16 payments
  6. XIFAXAN $266 21 payments
  7. STEGLATRO $259 19 payments
  8. JANUVIA $259 19 payments
  9. JARDIANCE Diabetes $257 14 payments
  10. VRAYLAR $233 6 payments
  11. Other $6,316 412 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

2,858

Median for Internal Medicine: 777

Drug cost

$128,051

Median for Internal Medicine: $73,373

Branded share of claims

13.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 39 $44,148
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $14,206
Xarelto Rivaroxaban Brand 13 $10,911
Breo Ellipta Fluticasone/Vilanterol Brand 18 $10,742
Entresto Sacubitril/Valsartan Brand 11 $7,815
Arnuity Ellipta Fluticasone Furoate Brand 15 $4,792
Atorvastatin Calcium Generic 245 $3,034
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 17 $2,303
Amlodipine Besylate Generic 296 $2,043
Albuterol Sulfate Hfa Albuterol Sulfate Brand 62 $1,885

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$3,636

Medicare's payments for the services billed

Medicare patients

103

Average age 75

Services billed

113

54 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 51%
Arthritis 51%
Chronic kidney disease 41%
Heart failure 36%
Ischemic heart disease 29%
COPD 29%
Atrial fibrillation 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $33
$33 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $23
$23 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $15
$15 — —
ZEPBOUND
  • Lilly USA, LLC $15
$15 — —
RYBELSUS
  • Novo Nordisk Inc $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record